45.68 USD
+0.58 (+1.29%)
45.68 USD
0 (0%)
Taking everything into account, SUPN scores 5 out of 10 in our fundamental rating. SUPN was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of SUPN get a neutral evaluation. Nothing too spectacular is happening here. SUPN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SUPN was profitable.
In the past year SUPN had a positive cash flow from operations.
In the past 5 years SUPN has always been profitable.
SUPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.35%, SUPN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
SUPN's Return On Equity of -1.82% is fine compared to the rest of the industry. SUPN outperforms 77.60% of its industry peers.
SUPN has a better Return On Invested Capital (2.34%) than 79.69% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
In the last couple of years the Profit Margin of SUPN has declined.
With a decent Operating Margin value of 6.08%, SUPN is doing good in the industry, outperforming 79.17% of the companies in the same industry.
In the last couple of years the Operating Margin of SUPN has declined.
SUPN has a Gross Margin of 89.91%. This is amongst the best in the industry. SUPN outperforms 92.19% of its industry peers.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SUPN has more shares outstanding
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SUPN has an Altman-Z score of 5.51. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
SUPN's Altman-Z score of 5.51 is fine compared to the rest of the industry. SUPN outperforms 75.00% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.51 |
ROIC/WACC0.26
WACC9.14%
2.3 Liquidity
SUPN has a Current Ratio of 1.80. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
SUPN has a worse Current ratio (1.80) than 65.10% of its industry peers.
SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.56, SUPN is doing worse than 60.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
SUPN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.32%.
Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 6.93% on average per year.
SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 4.54%.
SUPN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.00% yearly.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.52% yearly.
Based on estimates for the next years, SUPN will show a quite strong growth in Revenue. The Revenue will grow by 14.90% on average per year.
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.52%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.74 indicates a correct valuation of SUPN.
Based on the Price/Earnings ratio, SUPN is valued cheaply inside the industry as 86.98% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of SUPN to the average of the S&P500 Index (26.46), we can say SUPN is valued slightly cheaper.
With a Price/Forward Earnings ratio of 14.74, SUPN is valued correctly.
SUPN's Price/Forward Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 82.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.10. SUPN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.74 | ||
| Fwd PE | 14.74 |
4.2 Price Multiples
79.69% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
78.65% of the companies in the same industry are more expensive than SUPN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.02 | ||
| EV/EBITDA | 17.15 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)2.13
EPS Next 2Y2.48%
EPS Next 3Y10.42%
5. Dividend
5.1 Amount
No dividends for SUPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45.68
+0.58 (+1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners109.54%
Inst Owner Change-3.26%
Ins Owners4.2%
Ins Owner Change2.79%
Market Cap2.62B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target61.71 (35.09%)
Short Float %9.48%
Short Ratio5.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)38.13%
PT rev (3m)40.7%
EPS NQ rev (1m)-65.08%
EPS NQ rev (3m)-55.75%
EPS NY rev (1m)17.89%
EPS NY rev (3m)24.84%
Revenue NQ rev (1m)-3.13%
Revenue NQ rev (3m)1.01%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)3.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.74 | ||
| Fwd PE | 14.74 | ||
| P/S | 3.84 | ||
| P/FCF | 37.02 | ||
| P/OCF | 36.44 | ||
| P/B | 2.5 | ||
| P/tB | 8.53 | ||
| EV/EBITDA | 17.15 |
EPS(TTM)3.1
EY6.79%
EPS(NY)3.1
Fwd EY6.78%
FCF(TTM)1.23
FCFY2.7%
OCF(TTM)1.25
OCFY2.74%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.13
Graham Number35.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROCE | 3.81% | ||
| ROIC | 2.34% | ||
| ROICexc | 3.16% | ||
| ROICexgc | 38.99% | ||
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% | ||
| FCFM | 10.38% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.32% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | 5.51 |
F-Score4
WACC9.14%
ROIC/WACC0.26
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-8.49%
EPS Next 2Y2.48%
EPS Next 3Y10.42%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.29%
Revenue Next 2Y15.81%
Revenue Next 3Y15.03%
Revenue Next 5Y14.9%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year-16.93%
EBIT Next 3Y25.95%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
Can you provide the valuation status for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
What is the valuation of SUPERNUS PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 14.74 and the Price/Book (PB) ratio is 2.5.
How financially healthy is SUPERNUS PHARMACEUTICALS INC?
The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.